Day One Biopharmaceuticals Inc [DAWN] stock is trading at $14.80, up 7.95%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DAWN shares have gain 7.40% over the last week, with a monthly amount glided 13.32%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on April 24, 2024, when Needham reiterated its Buy rating and also boosted its price target to $33 from $30. Previously, BofA Securities downgraded its rating to Underperform on April 25, 2023, and dropped its price target to $9. On February 08, 2023, CapitalOne initiated with a Overweight rating and assigned a price target of $40 on the stock. Oppenheimer started tracking the stock assigning a Perform rating. H.C. Wainwright initiated its recommendation with a Buy and recommended $35 as its price target on December 15, 2022. Needham started tracking with a Buy rating for this stock on December 14, 2022, and assigned it a price target of $40. In a note dated December 05, 2022, Goldman initiated an Buy rating and provided a target price of $45 on this stock.
Day One Biopharmaceuticals Inc [DAWN] stock has fluctuated between $9.67 and $18.07 over the past year. Currently, Wall Street analysts expect the stock to reach $42.5 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $14.80 at the most recent close of the market. An investor can expect a potential return of 187.16% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Gross Profit Margin for this corporation currently stands at -0.05% with Operating Profit Margin at -405.31%, Pretax Profit Margin comes in at -373.1%, and Net Profit Margin reading is -373.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -1.26 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.11 points at the first support level, and at 13.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.27, and for the 2nd resistance point, it is at 15.75.
Ratios To Look Out For
For context, Day One Biopharmaceuticals Inc’s Current Ratio is 10.93. As well, the Quick Ratio is 10.93, while the Cash Ratio is 9.06.
Transactions by insiders
Recent insider trading involved Ramasastry Saira, Director, that happened on Jun 21 ’24 when 10000.0 shares were sold. HEAD OF R&D, Blackman Samuel C. completed a deal on Jun 10 ’24 to sell 30000.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Bender Jeremy sold 7873.0 shares on May 16 ’24.
